Humira's patent cliff status in 2024 indicates that the drug has already faced significant patent expirations, leading to the availability of biosimilar versions in the United States. AbbVie's primary patents for Humira have expired, allowing for market entry of interchangeable biosimilars.
When did Humira's US patents expire?
The key patents protecting Humira in the United States began expiring around 2016. However, AbbVie employed various strategies, including additional patents, to extend market exclusivity. Despite these efforts, the core patents have now lapsed, paving the way for biosimilar competition.
What does the Humira patent cliff mean for AbbVie?
The patent cliff for Humira has resulted in a substantial decline in its sales for AbbVie. With the introduction of biosimilars, particularly in the U.S. starting in 2023, the company has experienced a significant drop in revenue generated from the blockbuster drug. AbbVie has been preparing for this event by diversifying its product portfolio and investing in new drug development [1].
Which biosimilars are available for Humira?
Several companies have launched or are planning to launch biosimilars to Humira in the U.S. These include Amgen's Amjevita, Boehringer Ingelheim's Cyltezo, Coherus BioSciences' Yusimys, and Sandoz's Hyrimoz, among others. These biosimilars are approved for all of Humira's indications [2].
How do Humira biosimilars compare to the original drug?
Biosimilars are approved by regulatory agencies, like the U.S. Food and Drug Administration (FDA), to be highly similar to the reference biologic drug (Humira in this case). They must demonstrate no clinically meaningful differences in terms of safety, purity, and potency. While they are expected to be therapeutically equivalent, they are not identical to the reference product due to minor variations inherent in biological manufacturing processes. Interchangeable biosimilars, a subset of biosimilars, can be substituted for the reference product by a pharmacist without prescriber intervention under certain conditions [3].
What is the expected impact of biosimilars on Humira's price?
The introduction of biosimilars is generally expected to lower the cost of treatment for Humira. Competition from multiple biosimilar manufacturers typically drives down prices, making the therapy more accessible to patients and potentially reducing healthcare system costs.
What are the next steps for Humira's patent landscape?
While the main patents have expired, further litigation or challenges regarding secondary patents could potentially emerge, although their impact is likely to be limited given the current market entry of biosimilars. The focus now shifts to the market dynamics of biosimilar adoption and their pricing strategies. Information on patent expirations and litigation for biologics like Humira can be tracked on platforms such as DrugPatentWatch.com [4].
---
Sources:
1. https://www.abbvie.com/
2. https://www.fda.gov/drugs/biosimilars/approved-biosimilar-products-graphical-timeline
3. https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-biosimilar-substitution-frequently-asked-questions
4. https://drugpatentwatch.com/